ac investment research

Should I Buy NASDAQ:KIN Stock? (7% Forecasted Return)

When an issuer has a shared revolving credit facility with a captive finance entity, for purposes of calculating the issuer's liquidity sources, we net outstanding commercial paper at the captive from the revolver's borrowing availability. In these cases, we generally use an estimate of peak CP borrowings at the captive to avoid potentially overstating sources available to the issuer over a 12- to 24-month period.For companies in more volatile sectors, we assess the resiliency of liquidity through a cycle. If we do not believe the resulting descriptor reflects sustainable liquidity characteristics, we could adjust our liquidity assessment downward. For example, we could lower our liquidity assessment on a volatile company to strong from exceptional if we believe key quantitative measures typical of exceptional liquidity are not sustainable over the forecast period. This could especially be true if we believe there is a higher prospect of ratios weakening from the peak of an economic cycle.When assessing strong or exceptional liquidity, we include all forecasted capital expenditures over the next 24 months, including discretionary growth capital spending. We estimate KIN Kindred Biosciences stock forecast parameters by: Tri-tet Oscillators with ANOVA because of the firm's business is modestly more concentrated than average for peers, and the concentration represents modest incremental risk above what is captured in the anchor, but it is not a key credit weakness (7% Forecasted Return)

NASDAQ:KIN Price Targets, Stock Forecast (Buy or Sell) as of 11 Jun 2022 for (n+4 weeks)

Stock: KIN Kindred Biosciences

Time series to forecast n: 11 Jun 2022 for (n+4 weeks)

x axis:Likelihood %
y axis:Potential Impact %
z axis:Color (yellow to green) Technical Analysis %

AC Investment Research

In our experiment, we focus on an approach known as Decision making using game theory. We apply principles from game theory to model the relationships between rating actions, news, market signals and decision making.

301 Massachusetts Avenue Cambridge, MA 02139 667-253-1000